Meloxicam and diclofenac do not change VEGF and PDGF-ABserum levels of platelet-rich plasma

Utku, Burkay; Dönmez, Gürhan; Erişgen, Gülriz; Akin, Senay; Demirel, Haydar A.; Korkusuz, Feza; Doral, Mahmut Nedim

doi:10.3906/sag-1602-60

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The investigators found no differences in levels of growth factors in the experimental groups compared with in controls. 70 Further evidence to support the lack of effect of cyclooxygenase (COX) 2 inhibition on PRP protein release came from a study in dogs. Ludwig et al 40 showed no statistically significant decreases in TFG-β1, PDGF-BB, or thromboxane B2 release in PRP in dogs given carprofen compared with in controls when activated in vitro via human-γ-thrombin.…”

Section: Resultsmentioning

confidence: 99%

“…The investigators found no differences in levels of growth factors in the experimental groups compared with in controls. 70 Further evidence to support the Mixed effect a AA, arachidonic acid; ADP, adenosine diphosphate; ASA, aspirin; COX-2, cyclooxygenase 2; FGF, basic fibroblast growth factor; GDF-11, growth differentiation factor 11; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; IL, interleukin; LR, leukocyte-rich; NSAID, nonsteroidal anti-inflammatory drug; PDGF, platelet-derived growth factor; PRGF, platelet-rich growth factor; PRP, platelet-rich plasma; PRPP, platelet-rich plasma product; TGF-b1, transforming growth factor b-1; TNF-a, tumor necrosis factor a; TRAP-6, thrombin receptor-activated protein 6; TXB2, thromboxane B2; VEGF, vascular endothelial growth factor. The term anabolic factors means that studies attempted to measure growth factors, inflammatory cytokines, and other molecules believed to stimulate platelet activation and wound healing.…”

Section: In Vitro Analysesmentioning

confidence: 99%

See 1 more Smart Citation

Is Antiplatelet Therapy Contraindicated After Platelet-Rich Plasma Treatment? A Narrative Review

Magruder

Rodeo

2021

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

Background: Antiplatelet therapies are often withheld before and after platelet-rich plasma product (PRPP) administration due to theoretical concerns that therapies that inhibit the function of platelets would inhibit the effects of PRPP. Purpose/Hypothesis: The purpose of this study was to evaluate the effect that antiplatelet therapies have on the ability of PRPP to stimulate wound healing and tissue regeneration. Our hypothesis was that antiplatelet therapies would have highly heterogeneous effects on the biological activity of PRPP. Study Design: Narrative review. Methods: The Medline database was searched via PubMed to identify all studies related to PRPP and antiplatelet therapies, yielding 1417 publications. After the search was confined to articles published after 1995, there were 901 articles remaining. All abstracts were then screened to identify animal or human clinical studies that focused on growth factor or inflammatory cytokine production or treatment outcomes. We limited our analysis to studies reporting on orthopaedic pathologies and in vitro studies of antiplatelet therapies. Ultimately, 12 articles fit the search criteria. Results: The majority of studies reported on the use of nonsteroidal anti-inflammatory drugs as antiplatelet therapy. The majority of studies were in vitro analyses of growth factors, inflammatory cytokines, or cell viability, whereas 1 study examined clinical outcomes in an animal model. None of the studies investigated clinical outcomes in humans. All of the studies showed no effect or mixed effects of antiplatelet therapies on PRPP efficacy. One study showed PRPP recovery to baseline function after a 1-week washout period. Conclusion: The literature did not provide support for the common clinical practice of withholding antiplatelet therapies in patients being treated with PRPP.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: In Vitro Analysesmentioning

confidence: 99%

Is Antiplatelet Therapy Contraindicated After Platelet-Rich Plasma Treatment? A Narrative Review

Magruder

Rodeo

2021

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

show abstract

“…In vivo studies showed that PRP may have an anti-inflammatory effect by inhibiting the NF-KB pathway. (Utku et al, 2017) Each millilitre of PRP solution contains 1.5-2 million platelets, which represents a 5-fold increase in platelet and growth factors (Lai et al, 2015). In contrast, DP shows its effect by increasing PDGF levels.…”

Section: Discussionmentioning

confidence: 99%

Do Pain and Function Improve after Dextrose Prolotherapy or Autologous Platelet-Rich Plasma Injection in Longstanding Groin Pain?

Özkan¹,

Torğutalp²,

Levend³

et al. 2020

Monten. J. Sports Sci. Med.

Self Cite

View full text Add to dashboard Cite

Longstanding groin pain is a non-infectious and inflammatory chronic condition that causes inguinal pain in athletes. We compared dextrose prolotherapy (15% dextrose solution) and platelet-rich plasma (autologous platelet gel, plasma rich in growth factors, platelet concentrate) injections in male soccer players with longstanding groin pain. Forty elite male soccer players, ages between 13 and 33, with longstanding groin pain were treated. Patients were randomly divided into the dextrose prolotherapy (n= 9) and platelet-rich plasma injection (n= 6) groups. Following three injections, all patients were enrolled in the 12-week progressive home exercise protocol. Pain and function were assessed using the visual analogue (VAS) and Nirschl Pain Phase Scale (NPPS) scores before, one month after, and six months after the injection, respectively. VAS and NPPS scores decreased in both of the dextrose prolotherapy and the platelet-rich plasma injection groups. A decrease in pain and improvement in function were evident at a month after injection, and they remained favourable at the end of six months (VAS overall, p <0.001 and p= 0.003, respectively) (NPPS overall, p <0.001 and p= 0.007, respectively). A difference between the dextrose prolotherapy and the platelet-rich plasma injection groups was not observed at both time points (VAS, p= 0.3, p= 0.7, and p= 0.6 respectively) (NPPS, p= 0.6, p= 0.9, and p= 0.9 respectively). Dextrose prolotherapy and platelet-rich plasma injections decreased pain and improved function in longstanding groin pain treatment of male soccer players. These treatments should be considered in patients who are not responding to conservative treatment modalities. KEY WORDS longstanding groin pain, athletic pubalgia, injection, symphysis pubis, bone marrow oedema Different treatments have been recommended for longstanding groin pain, ranging from conservative management to surgical procedures (

show abstract

“…There was no reduction in the release of anabolic growth factors when patients used acetylsalicylic acid or acetylsalicylic acid with clopidogrel [ 37 ]. NSAIDs such diclofenac and meloxicam did not alter the release of VEGF and PDGF-AB levels of PRP [ 38 ]. There was no difference in thrombin production and platelet activation in response to TRAP-6, but there was significantly decreased ADP-induced platelet activation [ 39 ].…”

mentioning

confidence: 99%

Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection

2022

View full text Add to dashboard Cite

show abstract

Meloxicam and diclofenac do not change VEGF and PDGF-ABserum levels of platelet-rich plasma

Cited by 8 publications

References 27 publications

Is Antiplatelet Therapy Contraindicated After Platelet-Rich Plasma Treatment? A Narrative Review

Is Antiplatelet Therapy Contraindicated After Platelet-Rich Plasma Treatment? A Narrative Review

Do Pain and Function Improve after Dextrose Prolotherapy or Autologous Platelet-Rich Plasma Injection in Longstanding Groin Pain?

Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection

Contact Info

Product

Resources

About